Jiménez-Alcaide E, García-Fuentes C, Hernández V, et al. - Findings corroborated that men experienced greater severity of COVID-19 (coronavirus disease 2019). However, androgen deprivation therapy (ADT) administration in prostate cancer (PC) patients failed to avert the risk of severe COVID-19.

• This is a retrospective analysis of patients managed for COVID-19 with a previous diagnosis of PC.

• Of 2,280 patients treated for COVID-19, men showed a worse course of disease.

• A total of 1,349 patients registered in the PC database, 156 were receiving ADT and 1,193 were not.

• Among those, COVID-19 affected 61 (4.52%) PC patients, 11 (18.0%) belonged to the ADT group, and 50 (82.0%) to the non-ADT group.

• Concerning ADT’s impact on disease course, statistically significant differences were identified neither in the death rate nor in the presence of severe COVID-19.

• ADT was not found to be a protective factor for worse clinical evolution or death, post-adjustment for clinically relevant comorbidities.